Delivering on predictions made at major liver disease meetings over the past year, researchers said two experimental panvirals are curing hepatitis patients who had not been helped by earlier direct-acting antivirals.
In what researchers said was the first study of DAAs in children with HCV, UK researchers reported the drugs were effective and well tolerated. Questions remain about whther they might have any negative effects farther out.
The best treatment so far for primary sclerosing cholangitis, a rare and devastating inflammatory disease that typically strikes people in late adolescence or early adulthood, is liver transplant. But a phase 2 trial of norursodeoxycholic acid showed efficacy.